Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2021 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates

Announced strategic $125 million non-dilutive financing for tavapadon Welcomed Abraham Ceesay as President Appointed Scott Akamine as Chief Legal Officer Phase 1b trial for CVL-231 in...
May 04, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
April 29, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Report First Quarter 2021 Financial Results on Monday, May 17, 2021

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
April 21, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Appoints Abraham N. Ceesay as President

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the...
April 13, 2021 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon

Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson’s disease through planned NDA submission Data readouts from tavapadon...
March 24, 2021 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results

Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021 IND submitted for CVL-871 in dementia-related apathy Conference call and webcast...
March 22, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Present at the Stifel 3rd Annual CNS Day Event

CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
February 24, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
February 23, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
January 28, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs

Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator Company Expects to File U.S. IND Applications in 2021 for PDE4B and Kappa Opioid...